Effectiveness and Safety of High Dose Oral Ibuprofen versus Standard Dose for Treatment of Preterm Infants with Patent Ductus Arteriosus

Abstract

Background: One of the most significant changes needed for the transition to extrauterine life is the ductus arteriosus (DA) closure, which is located in the fetal circulatory system between both the aortic arch and the pulmonary artery. The extended length of patent DA (PDA), that further raises premature mortality and morbidity, impairs hemodynamics. The effectiveness and tolerability of oral ibuprofen administered at regular and high doses to treat PDA were examined in this research. Patients and Methods: The newborn Critical Care Unit at Cairo University Pediatric Hospitals received 60 preterm neonates (Gestational age<36 weeks) with clinically severe PDA during the course of 2.5 years. A randomized controlled trial was used in the investigation. They were divided into two groups at random, with the first receiving oral ibuprofen at a standard dose (10, 5, 5 mg/kg/day) and the second receiving oral ibuprofen at a high dose (20, 10, 10 mg/kg/day) for three days straight. Results:The neonates in our experiment exhibited a considerable reduction in PDA size both before and after taking it, and no statistical considerable difference between two regimens of ibuprofen was existent. Despite the fact they stayed within the scope of normal range for age in the high-dose group, serum creatinine level rose by two to three times following ibuprofen treatment. To completely comprehend this conclusion, further study is needed. Conclusions: Our results show that regular-dose ibuprofen for PDA closure is just as effective as high-dose ibuprofen with fewer side effects.